具RGD及組織蛋白去乙醯酶(HDAC)抑制劑長春西汀側基之RAFT共聚高分子--新穎抗癌藥物傳遞系統用於乳癌治療之開發

The number of people diagnosed with cancer in developed countries is estimated at 12 million. Chemotherapeutics for cancer treatment must be administered with a balance between efficacy and safety. Due to this, physicians often have a very narrow therapeutic window. Through targeted, stimuli-responsive delivery, the drug concentration at the diseased site can be increased, thereby extending the therapeutic window. By doing this, the drug will only be released or activated when it reaches its target. Cancer affects a wide range of organs, and there are many types of cancer. A variety of cancer targets must be accommodated by delivery systems that can adapt easily to cytotoxic drugs. This proposal aims to develop polymer-HDAC inhibitor conjugates highly effective against breast cancer. In this project we will prepare RGD-modified pendant vinpocetine-derived hydroxamic acid HDAC inhibitors derived from RAFT polymers to provide a novel drug delivery system for breast cancer. In the final year, we plan to publish two high-impact research articles and one patent. I will write a review article on polymer nanocarriers that deliver tumor-specific HDAC inhibitors.Potential contribution to academics, national developments, or other applications